Clinical Trials

Several clinical trials sponsored by AstraZeneca have evaluated the small-molecule inhibitor AZD7762, primarily comprising Phase 1 open-label, dose-escalation studies in patients with advanced solid malignancies. These protocols assessed the compound's safety, tolerability, and pharmacokinetics when administered as a single agent or in combination therapies. Overall, recruitment across this clinical trial portfolio is officially documented as either completed or terminated.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00937664 TERMINATED
Cancer; Solid Tumors; Advanced Solid Malignancies
AstraZeneca
 2009-07 PHASE1
NCT00473616 TERMINATED
Advanced Solid Tumors; Cancer; Advanced Solid Malignancies
AstraZeneca
 2007-05 PHASE1
NCT00413686 COMPLETED
Solid Tumors
AstraZeneca
 2006-12 PHASE1
NCT00937664 Terminated
Cancer|Solid Tumors|Advanced Solid Malignancies
AstraZeneca
 2009-07 Phase 1
NCT00473616 Terminated
Advanced Solid Tumors|Cancer|Advanced Solid Malignancies
AstraZeneca
 2007-05 Phase 1
NCT00413686 Completed
Solid Tumors
AstraZeneca
 2006-12 Phase 1

(data from https://clinicaltrials.gov, updated on 2011-02-07)

Check the AZD7762 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

AZD7762 selectively binds to and inhibits checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2), thereby suppressing DNA damage response signaling pathways and impairing homologous recombination repair. This kinase inhibition abrogates the G2 cell cycle checkpoint and sensitizes malignant cells to DNA damage, promoting apoptosis and limiting progression in patients with advanced solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.